REGENXBIO Inc.
REGENXBIO Inc. (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing and commercializing gene therapies designed to address genetic defects by delivering functional genes to enable the production of therapeutic proteins or antibodies. The company's investigational therapies utilize… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What REGENXBIO Inc. does
In the company’s own words
REGENXBIO Inc. (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing and commercializing gene therapies designed to address genetic defects by delivering functional genes to enable the production of therapeutic proteins or antibodies. The company's investigational therapies utilize adeno-associated virus vectors from its proprietary NAV Technology Platform, which comprises over 100 AAV vectors that provide preferential tropisms for various tissues and efficient transgene delivery and expression.
The company's pipeline concentrates on three therapeutic areas: retinal diseases, neuromuscular diseases, and neurodegenerative diseases. Lead programs include surabgene lomparvovec (sura-vec, ABBV-RGX-314), developed in collaboration with AbbVie for wet age-related macular degeneration and diabetic retinopathy; RGX-202 for Duchenne muscular dystrophy; RGX-121 (clemidsogene lanparvovec) for Mucopolysaccharidosis type II; and RGX-111 for Mucopolysaccharidosis type I, the latter two developed through a strategic partnership with Nippon Shinyaku.
REGENXBIO has built integrated, end-to-end capabilities spanning research and development, preclinical and clinical development, scalable manufacturing, and commercialization. The company operates the REGENXBIO Manufacturing Innovation Center in Rockville, Maryland, a cGMP production facility supporting clinical and future commercial production. The company has developed proprietary manufacturing platforms including NAVXpress for high-yielding AAV vector production and NAVXcell custom cell lines designed to increase production efficiency.
The NAV Technology Platform generates revenue through sublicensing arrangements with biopharmaceutical companies, known as NAV Technology Licensees. Notable licensed programs include Novartis' Zolgensma and Itvisma for spinal muscular atrophy, both FDA-approved and used to treat thousands of patients. This partnering strategy provides capital to advance the company's internal pipeline while maintaining focus on its core development programs.
The company maintains expertise in delivery device systems for multiple routes of administration, including to the central nervous system and ocular regions. REGENXBIO's website is www.regenxbio.com.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- ROCKVILLE, MD
- Fiscal year end
- December
- CIK
- 1590877
- SIC
- 2836
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns REGENXBIO Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · REGENXBIO Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do REGENXBIO Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of REGENXBIO Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in REGENXBIO Inc.'s last four quarterly filings that the numbers alone won't show?”